ESR1 and breast cancer: This underscores the importance of early detection of ESR1 mutations in metastatic and recurrent settings, potentially guiding patient management, follow-up, and treatment planning.356 Clinical trial results have demonstrated the potential efficacy of lasofoxifene as a treatment for late-stage or metastatic ER + BC in women expressing constitutively active ERα mutations.